Bevacizumab Biosimilar Nears Market As Amgen Files First At FDA

16 Nov 2016

• By John Davis

What is believed to be the first biosimilar version of Roche's Avastin to be filed with the US FDA has come from Amgen working in collaboration with Allergan, with the two companies heading a dozen-strong group of companies racing to develop versions of the monoclonal antibody.

A biosimilar version of Roche/Genentech Inc.'s Avastin (bevacizumab) has been submitted to the US FDA by Amgen Inc. and Allergan PLC, underlining their product's leadership position among the dozen or so bevacizumab biosimilars in development, and the desire of the two US big pharma companies to broaden their oncology portfolios.

ABP 215 is the first bevacizumab biosimilar to be submitted for approval to the US FDA, Amgen believes. The product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Takeda Prepares Ground For Oveporexton In Narcolepsy

14 Jul 2025

• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.